Status:
COMPLETED
Post-Marketing Study Of The Safety Of Tygacil (Tigecycline)
Lead Sponsor:
Pfizer
Conditions:
Complicated Skin and Skin Structure Infections
Complicated Intra-abdominal Infections
Eligibility:
All Genders
Brief Summary
The purpose of this study is to collect post-marketing information on the safety of Tygacil in Filipino patients.
Detailed Description
Three-thousand or 10% of total number of patients given tigecycline will be included in the study
Eligibility Criteria
Inclusion
- All patients from the study center who received or will receive at least one dose of Tygacil according to the approved product indication.
Exclusion
- Previously discontinued Tygacil therapy due to significant safety concern.
Key Trial Info
Start Date :
April 1 2007
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 1 2010
Estimated Enrollment :
621 Patients enrolled
Trial Details
Trial ID
NCT00683332
Start Date
April 1 2007
End Date
May 1 2010
Last Update
July 8 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Manila, Philippines